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Abstract
Experimental autoimmune encephalomyelitis (EAE) is a frequently used animal model for the investigation of
autoimmune processes in the central nervous system. As such, EAE is useful for modelling certain aspects of
multiple sclerosis, a human autoimmune disease that leads to demyelination and axonal destruction. It is an
important tool for investigating pathobiology, identifying drug targets and testing drug candidates. Even
though EAE is routinely used in many laboratories and is often part of the routine assessment of knockouts
and transgenes, scoring of the disease course has not become standardized in the community, with at least
83 published scoring variants. Varying scales with differing parameters are used and thus limit comparability
of experiments. Incorrect use of statistical analysis tools to assess EAE data is commonplace. In experimental
practice the clinical score is used not only as an experimental readout, but also as a parameter to determine
animal welfare actions. Often overlooked factors such as the animal’s ability to sense its compromised
motoric abilities, drastic though transient weight loss, and also the possibility of neuropathic pain, make
the assessment of severity a difficult task and pose a problem for experimental refinement.
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EAE: a model for multiple sclerosis
Experimental autoimmune encephalomyelitis (EAE) is
the most commonly used animal model for multiple
sclerosis (MS), an autoimmune demyelinating disorder
of the human central nervous system (CNS). MS aﬀects
2.5 million people worldwide with a preponderance in
higher latitudes and developed countries. Usually MS
commences in early adulthood and is more common in
females. Aﬄicted individuals develop motor impair-
ment and cognitive dysfunction.1,2 Disease severity
can be assessed using the expanded disability status
scale (EDSS),3 a scale based mainly on a combination
of functional systems and ambulation. It serves to
document the course of the disease and to escalate ther-
apy if necessary. It is also used in clinical trials where
it helps to assess the eﬃcacy of the therapeutic agent.
To ensure inter-rater standardization, training in the
use of the EDSS score is delivered by an independent
online platform.4 Although MS is a uniquely human
disorder not observed spontaneously in other species,
animal models have helped greatly in increasing our
knowledge of MS. They served as useful tools in inves-
tigating the dynamics of both the immune system and
the CNS during neuroinﬂammation. Accordingly,
many of the MS drugs in use and under testing in
humans have been developed on the basis of experi-
mental data through EAE.5 EAE is, however, not a
single model but consists of a family of animal
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models induced through diﬀerent protocols, each
serving a diﬀerent experimental purpose. It was ﬁrst
described in the 1930s while investigating the neuro-
logical complications arising after the rabies vaccin-
ation.6 After a series of studies that showed myelin
destruction and perivascular inﬁltration in the CNS;7
in 1947, similarities between EAE and human MS were
described.8 Since then, EAE was established in a variety
of mammals such as monkeys, guinea pigs, cats, goats,
primates, rats and mice, and was used to investigate the
pathobiology of MS.9 In mice, active EAE is induced
by subcutaneous immunization with myelin compo-
nents and adjuvants. Self-tolerance is broken and ence-
phalitogenic eﬀector T-cells migrate into the CNS to
attack the myelin sheath.10 The ﬁrst clinical signs of
disease, characterized by ascending ﬂaccid paralysis,
appear 7–8 days after immunization, with disease peak-
ing often between days 14 and 15. The most commonly
used antigens, derived from myelin, are proteolipid pro-
tein (PLP), myelin oligodendrocyte glycoprotein
(MOG), and myelin basic protein (MBP). In both MS
and EAE, the CNS is inﬁltrated by T-cells, B-cells and
macrophages.11 Nevertheless, other aspects of the dis-
ease diﬀer between patients and can be modeled in
EAE. For instance, induction in C57BL/6 mice using
MOG35-55 peptide emulsiﬁed in complete Freund’s
adjuvant (CFA) and followed by Pertussis toxin (PT)
injection usually results in chronic disease.12 On the
other hand, induction in SJL/J mice using PLP131-
151 peptide in CFA results in a relapsing–remitting pat-
tern. Adoptive transfer EAE, or passive EAE, is a
model in which encephalitogenic T-cells are transferred
from myelin-immunized or diseased mice to naı¨ve
recipient mice.10 This method allows the direct assess-
ment of the eﬀector phase of EAE, or the particular
study of transferred cells types or hosts’ backgrounds.
Apart from active and passive EAE, transgenic models
were developed in which EAE develops spontaneously
(reviewed by Croxford and colleagues).13 One example
is of the T-cell receptor transgenic mice crossed with the
IgH knock-in mice, both speciﬁc for MOG,14 which
develop the disease within 28 days.
Scoring scales for EAE
Active, passive and spontaneous EAE, even though pre-
senting occasionally with diﬀerent symptoms and signs,
are usually assessed through some similar type of ‘EAE
scoring scale’. Nevertheless, the term ‘EAE scoring scale’
does not refer to a cohesive scoring scheme. In 2010, a
meta-analysis of EAE studies showed that 126 manu-
scripts have used 83 diﬀerent clinical EAE scoring
scales, mostly without giving any explanation on why
a particular system was chosen.15 EAE scoring usually
serves two purposes: (1) assessment of disease severity as
outcome value of the scientiﬁc study, and (2) provides a
parameter for the determination of animal welfare
actions. The EAE scales used range from 0 (no clinical
signs) to between 4 and 10. The highest number usually
corresponds to the death of the animal. Strikingly, even
scales that have the same range often do not have the
same increment, or the same increment does not corres-
pond to the same clinical description. The scoring scales
of Miller (2007)16 and Bachmann (1999)17 range from
0 to 5 (Table 1); but the ﬁrst is a ﬁve-point scoring
scale whereas the second is a 10-point scale. Adding to
the confusion, the same number of identiﬁers may
describe diﬀerent signs, e.g. in the Kalyvas (2004)
scale, a score 5 comprehends both hind limb paralysis
with forelimb weakness, and moribund states,18 two dis-
tinct conditions that are separated as scores 4 and 5,
respectively in most papers. In general, it is not or not
suﬃciently discussed why the used scale ﬁts the respect-
ive study. Ten-point scoring scales may be superior by
allowing a more accurate description of symptoms, and
provides a better distinction between recovering and
relapsing stages. They may therefore contribute to a
higher statistical power and lead to improved assess-
ment of changes in EAE progression. Such more
extended scales would also overcome partial scoring
(e.g. score 1.5 in Miller’s scale16), another issue
in EAE clinical monitoring which is often reported
without being appropriately accounted for in the
Methods sections. As it relies on the researcher’s experi-
ence, it is context-dependent and therefore subjective.
Nevertheless, one must note that while a larger range
within the scale (i.e. the number of identiﬁers to
choose from) is scientiﬁcally superior, the chances of
inter-observer and intra-observer variability will be
enhanced. In this regard, blinding experimental
groups to the observer is crucial. Finally, EAE in
mice carrying certain gene deﬁciencies, leads to atypical
EAE,19 which is often more severe and progressive.20
Atypical EAE involves axial-rotatory movements due
to inﬁltration and demyelination of the cerebellum and
brainstem, instead of the spinal cord, thus requiring a
diﬀerent scoring scheme (Table 1).20,21
Assessment of welfare
In most studies the EAE score, alone or in combination
with other parameters such as weight, deﬁnes animal
welfare actions. These commonly constitute provision
of food and water on the cage ﬂoor, mostly in jelliﬁed
form, and termination by euthanasia. In EAE, animal
well-being results from a combination of neurological
deﬁcits such as reduced motor control, the possibility of
nausea or neuropathic pain, and features associated
with any severe disease like weight loss and dehydra-
tion. Increasing loss of motor function clearly impairs
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the animals’ access to food and water, participation in
social activities and their ability to fend oﬀ cage mates.
Whether the animal realizes its disability and suﬀers
purely from comprehending this remains an open and
probably unanswerable question. In humans, hedonistic
adaptation appears to allow paraplegic patients a similar
quality of life as the healthy population.22 Weight loss
and dehydration, which are both easy to assess during
daily monitoring of the mice, have direct welfare rele-
vance and their assessment is often required by the
responsible animal welfare authorities. Mice can adapt
to a deprivation of up to 50% of water for one week.23
Nevertheless, due to daily scoring in EAE, dehydration
could be detected rather accurately by adopting the scale
established by Bekkevold and colleagues.23 In case of
dehydration, an intraperitoneal administration of saline
(maximum 80mL/kg)24 should be enough for full recov-
ery. By contrast to dehydration, critical weight loss,
often deﬁned as a reduction of 20% in body weight,
leads to termination of the experiment because mice
must be euthanized to abide with humane endpoints.
Although to the best of our knowledge there is no
direct causal relationship between weight loss and dis-
ease progression; in EAE mice frequently lose weight
transiently, correlating with higher scores and paraly-
sis.25 Thus, they are able to recover their weight when
disease ameliorates. This raises the question of whether a
20% weight loss constitutes a good termination point.
A report in ABH mice shows that these are highly sus-
ceptible to weight loss without any corresponding
increase in disease severity.26 In this study, mice lost
around 26% of weight during acute disease, followed
by almost complete recovery. Thus, if the authors
have rigidly applied the frequently pre-set guidelines of
20% body weight loss as the endpoint, they would
have killed most of their experimental subjects, without
gaining insight into the relapsing–remitting phase of
the disease that is characteristic of this strain and
which can be a source of valuable clinical information.26
Consequently, in EAE critical weight loss may have to
be deﬁned on a case-by-case basis in order to overcome
the problem of losing statistical power and scientiﬁcally
important data. In this regard, a European Union docu-
ment with practical guidelines on how to implement
Directive 2010/63/EU in EAE studies suggests using
35% weight loss as the humane endpoint, whenever
applicable, in order to maximize 3R practice.27 For
ABH mice, an endpoint based on body temperature
was suggested in one study: when body temperature
decreases below 31C, recovery is unlikely.26 An even
more stringent suggestion was made in a pertussis infec-
tion/vaccination study, where a lower body temperature
limit of 34.5C was shown to be a humane endpoint.
Nevertheless, future research in EAE using C57/BL6
also has to show whether temperature could be a
useful endpoint, and whether it justiﬁes the additional
handling of animals.28
Refinement opportunities
Current clinical scoring of EAE suﬀers from some obvi-
ous problems, most of which can be easily overcome.
Firstly, the community needs to come to agreement on
a commonly accepted scoring scheme that allows com-
parison of experiments. This may well be based on a
frequently practised 10-step scale. Also, since data from
clinical EAE scoring are generated within non-linear
scales, they must be analysed using non-parametrical
statistical tests such as the Mann–Whitney U or
Wilcoxon rank sum test. Even though this is long-
known, 50% of reports feature parametrical statistics.29
Application of correct tests and the corresponding
power calculations would strongly increase reproduci-
bility of EAE experiments. Blinding of EAE studies is
rarely reported, making inadvertent biases highly likely.
Since circadian rhythm aﬀects immune responses and
vice versa, induction and scoring should be performed
at identical times during an experiment.30,31 Though
only suitable for mice not yet paralysed, the use of
quantitative motor function tests such as the grip
strength and rotarod have been shown to help decrease
bias.25 Such motor assessment facilitates statistical ana-
lysis with parametric tests and thus increases power.
Treating weight loss as a humane endpoint criterion
should be questioned critically, as discussed above.
Littermate controls should be preferred over wild-
type mice bought from commercial suppliers to ensure
the genetic background diﬀers only by the factor in
study. Lastly, environmental stress and gut microbiome
may inﬂuence disease outcome,32 and should thus be
similar between experimental groups. Hence, preference
should be given to mixing mice of diﬀerent experimental
groups in the same cage from early age on and allowing
them to adapt to housing conditions.33 Thus, a unifying
system capable of eﬃciently and objectively inducing
and accessing disease progression and animal welfare
without causing extra discomfort to the animals should
be sought.
Recommendations and further 3R research
A common measurement in most EAE studies is the
assessment of clinical symptoms using scoring scales,
which not only yield experimental data but also deﬁne
welfare actions. EAE experiments would proﬁt greatly,
if researchers were to implement the following points:
(a) One common scale.
(b) Induction and measurement of disease at identical
time of the day.
Palle et al. 3
T
a
b
le
1
.
E
xa
m
p
le
s
o
f
e
xp
e
ri
m
e
n
ta
l
a
u
to
im
m
u
n
e
e
n
ce
p
h
a
lo
m
ye
li
ti
s
(E
A
E
)
sc
o
ri
n
g
sy
st
e
m
s.
M
il
le
r
(2
0
0
7
)1
6
B
a
ch
m
a
n
n
(1
9
9
9
)1
7
A
xi
a
l-
ro
ta
to
ry
E
A
E
2
0
B
e
b
o
(1
9
9
8
)3
4
B
it
tn
e
r
(2
0
1
4
)3
5
E
xp
a
n
d
e
d
d
is
a
b
il
it
y
st
a
tu
s
sc
a
le
(M
S
in
p
a
ti
e
n
ts
)3
0
N
o
cl
in
ic
a
l
si
g
n
s
N
o
cl
in
ic
a
l
si
g
n
s
N
o
cl
in
ic
a
l
si
g
n
s
0
N
o
cl
in
ic
a
l
si
g
n
s
N
o
cl
in
ic
a
l
si
g
n
s
N
o
cl
in
ic
a
l
si
g
n
s
0
.5
D
is
ta
l
li
m
p
ta
il
1
M
in
im
a
l
h
in
d
li
m
b
w
e
a
k
n
e
ss
P
a
rt
ia
l
li
m
p
ta
il
N
o
im
p
a
ir
m
e
n
t
1
L
im
p
ta
il
o
r
h
in
d
li
m
b
w
e
a
k
n
e
ss
L
im
p
ta
il
M
il
d
ti
lt
in
g
o
f
th
e
h
e
a
d
2
M
o
d
e
ra
te
h
in
d
li
m
b
w
e
a
k
n
e
ss
o
r
m
il
d
a
ta
xi
a
P
a
ra
ly
se
d
ta
il
M
in
im
a
l
im
p
a
ir
m
e
n
t
1
.5
L
im
p
ta
il
a
n
d
h
in
d
li
m
b
w
e
a
k
n
e
ss
3
M
o
d
e
ra
te
se
ve
re
h
in
d
li
m
b
w
e
a
k
n
e
ss
H
in
d
li
m
b
p
a
re
si
s
M
o
d
e
ra
te
im
p
a
ir
m
e
n
t
2
B
o
th
li
m
p
ta
il
a
n
d
li
m
b
w
e
a
k
n
e
ss
U
n
il
a
te
ra
l
p
a
rt
ia
l
h
in
d
li
m
b
p
a
ra
ly
si
s
M
a
rk
e
d
ti
lt
in
g
o
f
th
e
h
e
a
d
4
S
e
ve
re
h
in
d
li
m
b
w
e
a
k
-
n
e
ss
o
r
m
il
d
fo
re
li
m
b
w
e
a
k
n
e
ss
o
r
m
o
d
e
ra
te
a
ta
xi
a
H
in
d
li
m
b
p
a
ra
p
le
g
ia
S
e
ve
re
im
p
a
ir
m
e
n
t
2
.5
B
il
a
te
ra
l
p
a
rt
ia
l
h
in
d
li
m
b
p
a
ra
ly
si
s
5
P
a
ra
p
le
g
ia
w
it
h
m
o
d
e
r-
a
te
fo
re
li
m
b
w
e
a
k
n
e
ss
B
o
th
h
in
d
li
m
b
s
p
a
ra
ly
se
d
W
a
lk
in
g
re
st
ri
ct
e
d
to
<
2
0
0
m
3
P
a
rt
ia
l
h
in
d
li
m
b
p
a
ra
ly
si
s
C
o
m
p
le
te
b
il
a
te
ra
l
h
in
d
li
m
b
p
a
ra
ly
si
s
T
il
ti
n
g
o
f
th
e
b
o
d
y
6
P
a
ra
p
le
g
ia
w
it
h
se
ve
re
fo
re
li
m
b
w
e
a
k
n
e
ss
o
r
se
ve
re
a
ta
xi
a
Q
u
a
d
ri
p
a
re
si
s
C
o
n
st
a
n
t
a
ss
is
ta
n
ce
3
.5
C
o
m
p
le
te
b
il
a
te
ra
l
h
in
d
li
m
b
p
a
ra
ly
si
s
7
1
fo
re
li
m
b
p
a
ra
ly
se
d
W
h
e
e
lc
h
a
ir
b
o
u
n
d
4
C
o
m
p
le
te
h
in
d
li
m
b
p
a
ra
ly
si
s
a
n
d
p
a
rt
ia
l
fo
re
li
m
b
p
a
ra
ly
si
s
C
o
n
ti
n
u
o
u
s
a
xi
a
l
ro
ta
ti
o
n
8
Q
u
a
d
ri
p
le
g
ia
B
e
d
b
o
u
n
d
4
.5
M
o
ri
b
u
n
d
9
M
o
ri
b
u
n
d
H
e
lp
le
ss
b
e
d
p
a
ti
e
n
t
5
D
e
a
th
D
e
a
th
D
e
a
th
1
0
D
e
a
th
D
e
a
th
M
S
:
m
u
lt
ip
le
sc
le
ro
si
s.
[A
Q
2
]
4 Laboratory Animals 0(0)
(c) Induction and measurement of disease in a blinded
fashion.
(d) Use of littermate controls of the same genetic
background and hosting similar microbiomes.
(e) Use of non-parametric statistics for data analysis
and power calculation during experimental
planning.
(f) Allowance of up to 35% transient weight loss,
according to characteristics of the strain, EAE
induction paradigm and aim of the study.
(g) Consistent use of jelliﬁed food/water as welfare
action.
(h) Assessment of dehydration paired with respective
actions.
When the aim of a study is to describe small diﬀer-
ences at low scores, motor tests such as rotarod and
grip strength should be used and may increase the
power of the study. Future research has to show
whether neuropathic pain constitutes a relevant
animal welfare problem in EAE. In conclusion, EAE
scoring scales are a good example of tools that repre-
sent well-established and common practice, but which
need to be re-evaluated with a critical eye. Currently,
the variety of scoring scales and their analysis may con-
tribute to irreproducibility and failure in translation of
animal experiments.
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